Research progress of intraperitoneal hyperthermic perfusion chemotherapy after ad-vanced gastric cancer operation
10.3969/j.issn.1000-8179.2019.02.846
- VernacularTitle:进展期胃癌术后腹腔热灌注化疗的研究进展
- Author:
Hongbo WANG
1
;
Xin WANG
;
Si LIU
;
Pengyuan WANG
Author Information
1. 北京大学第一医院普通外科(北京市100034
- Keywords:
gastric cancer;
advanced stage;
intraperitoneal hyperthermic perfusion chemotherapy;
research progress
- From:
Chinese Journal of Clinical Oncology
2019;46(2):99-102
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer is one of the most common clinical malignant tumors; surgery is an important treatment for it. The postoper-ative 5-year survival rate of patients with advanced gastric cancer is low; postoperative tumor recurrence is an important factor influ-encing the prognosis of patients. With the continuous development of domestic medicine, the technology of intraperitoneal hyper-thermic perfusion chemotherapy is improved continuously, and is widely used in postoperative adjuvant therapy for patients with ad-vanced gastric cancer. Long-term clinical practice shows that prophylactic use of hyperthermic intraperitoneal chemotherapy for ad-vanced gastric cancer could significantly reduce the recurrence rate of gastric cancer and improve the 5-year survival rate of patients. It plays a positive role in improving the quality of life of patients and overall clinical curative effect. In this review, the clinical applica-tion of hyperthermic intraperitoneal chemotherapy for advanced gastric cancer in China was summarized.
